科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06990 科伦博泰生物

休市中 09-04 16:08:03

489.400

-7.400

-1.49%

最高509.500	最低486.800	成交量46.94万
今开505.000	昨收496.800	日振幅4.57%
总市值1,170亿	流通市值866.24亿	总股本2.39亿
成交额2.31亿	换手率0.27%	流通股本1.77亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科伦博泰生物","latestPrice":489.4,"timestamp":1788509283011,"preClose":496.8,"halted":0,"volume":469400,"delay":0,"changeRate":-0.014895330112721485,"floatShares":177000000,"shares":239000000,"eps":-1.9364302110627625,"marketStatus":"休市中","change":-7.4,"latestTime":"09-04 16:08:03","open":505,"high":509.5,"low":486.8,"amount":230924896,"amplitude":0.045692,"askPrice":489.8,"askSize":1300,"bidPrice":489.4,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.7576134330471599,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788744600000},"marketStatusCode":7,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":496.8,"openAndCloseTimeList":[[1788485400000,1788494400000],[1788498000000,1788508800000]],"volumeRatio":0.686586148721212,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990","defaultTab":"news","newsList":[{"id":"1156391309","title":"科伦博泰生物：东方证券股份有限公司减持，好仓比例降至4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156391309","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156391309?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:42","pubTimestamp":1788514953,"startTime":"0","endTime":"0","summary":"东方证券股份有限公司于2026年8月28日以每股均价514.6015港元卖出科伦博泰生物股份1.97万股，涉资约1013.76万港元。东方证券股份有限公司此次减持前持有科伦博泰生物好仓886.01万股，占比5.01%；减持后持股量为884.04万股，好仓比例降至4.99%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169955832","title":"科伦博泰生物：东方证券股份有限公司增持，好仓比例升至5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1169955832","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169955832?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:41","pubTimestamp":1788514913,"startTime":"0","endTime":"0","summary":"东方证券股份有限公司于2026年8月31日以每股均价492.91港元买入科伦博泰生物股份3.08万股，涉资约1518.16万港元。东方证券股份有限公司此次增持前持有科伦博泰生物好仓884.04万股，占比4.99%；增持后持股量为887.12万股，好仓比例升至5.01%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238859","title":"【券商聚焦】交银国际：医药行业收入稳健增长 多重利好推动盈利表现显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238859","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664238859?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:00","pubTimestamp":1788483634,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，1H26港股/A股医药行业整体收入增长4.7%/3.2%。创新药产业链增速领跑行业，服务板块复苏：1）港股/A股CXO收入整体增长29.2%/25.3%，（扣非）净利润增长23.4%/67.6%，在各子板块中增速最快，行业整体景气度和订单需求处于高位。2）核心成药板块收入增长17.8%/3.4%、利润增长62.7%/35.0%。其中生物药增速远超化药，在板块收入中的占比也进一步提升。3）医院、器械、诊断、疫苗等板块业绩有复苏趋势。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821","02096","LU0307460666.USD","06996","LU0588546209.SGD","LU0315179316.USD","01548","HK0000320264.USD","IE00B0JY6N72.USD","LU2543165471.USD","06990","01801","01093","09926","09996","KCE","LU1152091168.USD","01952","LU1251922891.USD","01530","03759","02268","BK1209","01951","LU1880383366.USD","02596","03692","BK1589","LU0348783233.USD","BK1515","HK0000306685.HKD","LU0856984785.SGD","IE00B543WZ88.USD","03329","BK1161","01276","SG9999004220.SGD","KURE","02273","00013","IE00B5MMRT66.SGD","LU0327786744.USD","06160","09966","LU0039217434.USD","LU1242518857.USD","01177","02162","02269","06078"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664879489","title":"汇添富基金管理股份有限公司增持科伦博泰生物(06990)3.08万股 每股作价约492.91港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664879489","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664879489?lang=zh_cn&edition=full","pubTime":"2026-09-03 19:17","pubTimestamp":1788434252,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，8月31日，汇添富基金管理股份有限公司增持科伦博泰生物(06990)3.08万股，每股作价492.9088港元，总金额约为1518.16万港元。增持后最新持股数目为887.12万股，最新持股比例为5.01%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","06990","BK1161","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197323262","title":"科伦博泰生物：汇添富基金管理股份有限公司增持，好仓比例升至5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197323262","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197323262?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:19","pubTimestamp":1788427153,"startTime":"0","endTime":"0","summary":"汇添富基金管理股份有限公司于2026年8月31日以每股均价492.9088港元买入科伦博泰生物（06990）H股3.08万股，涉资约1518.16万港元。汇添富基金管理股份有限公司此次增持前持有科伦博泰生物好仓884.04万股，占比4.99%；增持后持股量为887.12万股，好仓比例升至5.01%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123637054","title":"科伦博泰生物8月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1123637054","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123637054?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:36","pubTimestamp":1788424590,"startTime":"0","endTime":"0","summary":"四川科伦博泰生物医药股份有限公司于2026年9月3日发布公告，披露截至2026年8月31日的股份变动月报表。根据公告，报告期内公司法定/注册股本维持为人民币239,023,969元，其中包括176,822,257股面值为每股人民币1元的H股和62,201,712股面值为每股人民币1元的内资股，未发生增减变动。公司表示，现有股本规模满足香港联交所相关公众持股量要求，各项业务及股本状况均保持稳定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130601247","title":"科伦博泰生物：汇添富基金管理股份有限公司减持，好仓比例降至4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130601247","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130601247?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:25","pubTimestamp":1788341138,"startTime":"0","endTime":"0","summary":"汇添富基金管理股份有限公司于2026年8月28日以每股均价514.6015港元卖出1.97万股科伦博泰生物股份，涉资约1013.76万港元。汇添富基金管理股份有限公司此次减持前持有科伦博泰生物好仓886.01万股，占比5.01%；减持后持股量为884.04万股，好仓比例降至4.99%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664817446","title":"【生物医药小白投研】第七篇：看得懂基本面，更要把握交易节奏","url":"https://stock-news.laohu8.com/highlight/detail?id=2664817446","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664817446?lang=zh_cn&edition=full","pubTime":"2026-09-02 15:48","pubTimestamp":1788335280,"startTime":"0","endTime":"0","summary":"很多投资者的通病：基本面研究很透彻，看得懂管线、分得清BD、看得懂估值，但实操交易却总是不得要领。2）建议卖点：预期兑现、情绪高位重大临床数据落地、BD正式签约、药物获批等核心利好兑现；股价短期大幅拉升、估值透支未来预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650514068&idx=1&sn=04383d6542345b5ab37bff46d0980044&chksm=f3c9956fce9a29e7b20b133d9a101d486e4af7867027ae7c06fa93bfeea19f07b272ba5bb04e&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU0417516738.SGD","LU0455707207.USD","LU1188198961.HKD","LU1720050803.USD","IE00BPRC5H50.USD","LU1770034418.SGD","LU0348766576.USD","06990","LU2097828714.EUR","LU2476274308.USD","LU2476274720.SGD","LU0196878994.USD","LU0348784397.USD","LU0634319403.HKD","LU0326950275.SGD","LU1719994722.HKD","LU2097828805.USD","IE00B543WZ88.USD","LU0588546209.SGD","LU2778985437.USD","LU0561508036.HKD","LU0463099449.HKD","09926","LU0228659784.USD","LU0828237510.HKD","BK1588","LU0307460666.USD","LU2097828474.EUR","LU2242644610.SGD","LU2097828557.USD","LU1969619763.USD","LU2488822045.USD","01801","IE00B5MMRT66.SGD","LU1303224171.USD","LU2097828631.EUR","BK1500","LU0417516902.SGD","BK1574","LU1961090484.USD","LU1794554557.SGD","06160","LU0502904849.HKD","HK0000165453.HKD","LU0348783233.USD","LU0348827113.USD","KURE","BK1589","LU0348767384.USD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182577008","title":"异动解读｜科伦博泰生物盘中下跌3.4%，报503.0港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182577008","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182577008?lang=zh_cn&edition=full","pubTime":"2026-08-31 09:38","pubTimestamp":1788140327,"startTime":"0","endTime":"0","summary":"8月31日，科伦博泰生物盘中下跌3.4%，报503.0港元/股，成交额1326.44万港元。科伦博泰生物所在的生物科技行业整体承压，个股中，康希诺生物跌6.74%，百济神州跌3.21%，康方生物跌2.78%，信达生物跌2.23%，云顶新耀跌1.96%。科伦博泰生物主要从事肿瘤学、免疫学及其他治疗领域的创新药物研发、制造及商业化，核心产品包括TROP2 ADC芦康沙妥珠单抗等抗体药物偶联物。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662094216","title":"【生物医药小白投研】第五篇：读懂BD的价值逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662094216","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662094216?lang=zh_cn&edition=full","pubTime":"2026-08-28 16:50","pubTimestamp":1787907000,"startTime":"0","endTime":"0","summary":"在生物医药二级市场，BD是出现频率最高、对股价影响较为直接的核心词汇之一。但在A股、港股创新药赛道，能够对股价形成重大催化的BD交易，大多特指药物全球权益授权交易。首付款是海外顶级药企对药物当下真实价值的投票，是BD含金量的核心判断依据。BD出海让一款药物同时覆盖国内+全球市场，估值逻辑彻底升级。例如科伦博泰、信达生物等，持续兑现出海BD，研发实力全球认可。NO.6小白必须警惕以下BD误区误区一：BD落地股价必涨。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650514013&idx=2&sn=a94c778f97f0744682cc347b39421f20&chksm=f382c39a6e71d39b1967e69c7fe65ec399f4658e5a18b93c3b2c95e183487c32d8cdc7dd65d9&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["06160","KURE","LU0502904849.HKD","ONC","LU1770034418.SGD","LU2097828631.EUR","LU1303224171.USD","BK1588","BK1583","LU2097828557.USD","LU0828237510.HKD","06990","LU0307460666.USD","LU0196878994.USD","LU1188198961.HKD","LU2242644610.SGD","01801","BK1593","LU1251922891.USD","LU0463099449.HKD","688235","LU2097828714.EUR","LU2097828805.USD","LU1969619763.USD","BK1589","LU0455707207.USD","LU1719994722.HKD","BK1161","LU2097828474.EUR","01530","LU0244354667.USD","BK1500","LU0326950275.SGD","LU2328871848.SGD","LU0588546209.SGD","LU2488822045.USD","HK0000165453.HKD","LU0228659784.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192810746","title":"异动解读｜科伦博泰生物盘中下跌3.16%，报521.0港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192810746","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192810746?lang=zh_cn&edition=full","pubTime":"2026-08-24 10:43","pubTimestamp":1787539437,"startTime":"0","endTime":"0","summary":"8月24日，科伦博泰生物盘中下跌3.16%，报521.0港元/股，成交额7350.27万港元。科伦博泰生物所在的生物科技行业中，板块整体表现偏弱，个股中，云顶新耀涨1.34%，康方生物跌1.33%，信达生物跌3.17%，百济神州跌3.51%，康希诺生物跌4.48%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661412492","title":"科伦博泰半年报首盈背后：一位75岁创业者的向上之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2661412492","media":"锦缎","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661412492?lang=zh_cn&edition=full","pubTime":"2026-08-24 07:28","pubTimestamp":1787527680,"startTime":"0","endTime":"0","summary":"8月17日，科伦博泰生物发布2026年中期业绩。这是科伦博泰上市以来首次实现半年度盈利。站在这一里程碑前的，是75岁的刘革新。03118亿美元与兑现科伦博泰真正的拐点，出现在2022年。一旦递交，科伦博泰将触发新的里程碑付款，并开启长期销售分成窗口。科伦博泰的战略高度依赖刘革新个人的判断力。75岁的刘革新还在前线，科伦博泰的“向上”，也还在路上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8vqEVRQntVo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"ifeng_tech","symbols":["LU0196878994.USD","BK1161","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660020034","title":"mRNA癌症疫苗实现历史性突破 易方达生物医药ETF(03186)港美股双布局捕捉创新红利","url":"https://stock-news.laohu8.com/highlight/detail?id=2660020034","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660020034?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:45","pubTimestamp":1787215545,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月19日，Moderna与默沙东公布，个人化mRNA癌症疫苗联合Keytruda，在黑色素瘤三期试验期中分析达标。截至2026年8月20日，易方达生物医药ETF  是港交所上市生物医药主题ETF中，唯一同时配置港股及美股生物医药成分的产品。这些成份股的均衡配置，让该ETF能够捕捉医药板块的整体修复行情。本次mRNA癌症疫苗达标，再次说明医疗创新本身就是科技突破，而不只是防御型板块。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","02162","03186","LU0196878994.USD","159929","09688","159646","06990","BK1583","BK1161","BK1587","BK1588","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660023238","title":"【生物医药小白投研】第一篇：打破认知盲区，建立底层框架","url":"https://stock-news.laohu8.com/highlight/detail?id=2660023238","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660023238?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:30","pubTimestamp":1787214600,"startTime":"0","endTime":"0","summary":"生物医药是A股和港股中最特殊的赛道，没有之一。本篇旨在帮助读者打破固有思维，搭建生物医药投资的底层认知框架，为后续的选择、排雷、交易体系打好基础。康方生物：2025年商业化产品销售收入30.33亿元，同比增长51.48%。目前该公司已有4款产品获批上市。典型案例是2026年ASCO期间，康方生物和信达生物等发布了重磅临床数据，但当日股价表现平平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650513943&idx=1&sn=7cbba7ab46d98a94d953d8e9b60809e2&chksm=f30e7cf71bc535c0c64240524852e4b36187629cca446e9bd382f04ea70a74b68d1ffd38d5ce&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["IE0008369823.USD","IE0008368742.USD","BK1521","LU0880133367.SGD","LU0561508036.HKD","LU0244354667.USD","LU1226287875.USD","LU2097828631.EUR","IE00BPRC5H50.USD","LU2488822045.USD","LU1951186391.HKD","LU0067412154.USD","LU1226287792.SGD","LU0140636845.USD","LU2097828557.USD","LU2097828805.USD","LU1328277881.USD","LU1226287529.USD","06990","01801","01093","09926","LU2328871848.SGD","LU2778985437.USD","LU1152091168.USD","LU1720050803.USD","02396","LU2097828714.EUR","LU2039709279.SGD","LU0501845795.SGD","03692","LU0634319403.HKD","LU2097828474.EUR","LU0348783233.USD","LU2242644610.SGD","LU0463099449.HKD","LU0326950275.SGD","LU0348735423.USD","06872","LU0540923850.HKD","SG9999004220.SGD","KURE","LU0348767384.USD","IE00B5MMRT66.SGD","IE00BZ08YS42.EUR","01177","IE00BZ08YR35.GBP","IE00B031HY20.USD","BK1583","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660890406","title":"交银国际：科伦博泰生物维持“买入”评级 目标价上调至642港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660890406","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660890406?lang=zh_cn&edition=full","pubTime":"2026-08-20 14:02","pubTimestamp":1787205720,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端交银国际发布研报称，将科伦博泰生物（06990）目标价调高至642港元，维持“买入”评级。该行指，科伦博泰生物上半年产品销售超预期，商业化及研发投入持续加速，Sac-TMT 全面挺进 1L NSCLC领域，新一代偶联药物矩阵雏型初显。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-20/doc-ininxvfu2077109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EWH","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130882610","title":"异动解读｜科伦博泰生物盘中上涨4.11%，多家投行密集上调目标价提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1130882610","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130882610?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:42","pubTimestamp":1787190132,"startTime":"0","endTime":"0","summary":"8月20日，科伦博泰生物盘中上涨4.11%，报548.0港元，成交额7198.87万港元，较前一交易日回调后明显反弹。消息面上，8月19日多家国际投行密集发布研报上调目标价：美银证券将目标价上调至644.4港元，里昂上调至626.4港元，瑞银此前已上调至678港元，均维持\"买入\"评级。科伦博泰生物是一家主要从事肿瘤学、免疫学领域创新药物研发、制造及商业化的公司，核心产品包括TROP2 ADC芦康沙妥珠单抗等。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦博泰生物盘中上涨4.11%，多家投行密集上调目标价提振市场信心","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660016410","title":"美银证券：升科伦博泰生物-B(06990)目标价至644.4港元 料全年扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2660016410","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660016410?lang=zh_cn&edition=full","pubTime":"2026-08-19 15:07","pubTimestamp":1787123223,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美银证券发布研报称，科伦博泰生物-B上半年收入同比增长2.9%，期内药品销售收入同比增长逾倍，中期净利润3.88亿元人民币，实现扭亏，但主要是来自于和解收入等其他收入带动。经营现金流转正至3.39亿元人民币，现金及金融资产约47.8亿元人民币，为管线开发及商业化提供稳固资金基础。目标价由581港元上调至644.4港元，评级维持“买入”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","06990","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660986412","title":"【券商聚焦】招银国际维持科伦博泰生物（06990）买入评级 对sac-TMT的全球开发前景保持信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2660986412","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660986412?lang=zh_cn&edition=full","pubTime":"2026-08-19 13:22","pubTimestamp":1787116932,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际研报指，科伦博泰生物 公布1H26业绩：总收入为人民币9.78亿元，其中药品销售收入6.57亿元，达到该机构此前全年预测的53%，超出该机构预期。Sac-TMT已成为默沙东的基石ADC资产，目前共有17项全球III期临床进行中。同时，该机构认为默沙东正在探索sac-TMT与其PD-1/VEGF双抗MK-2010的联用，默沙东进一步的联用探索将构成增量催化剂该机构对sac-TMT的全球开发前景保持信心。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988717","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660414398","title":"里昂：科伦博泰生物-B维持“跑赢大市”评级 目标价升至626.4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660414398","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660414398?lang=zh_cn&edition=full","pubTime":"2026-08-19 12:43","pubTimestamp":1787114580,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端里昂发布研报称，科伦博泰生物-B（06990）上半年收入同比增长2.9%，商业化收入因sac-TMT的适应症及渠道扩张而同比强劲增长112.1%。净利润达3.88亿元人民币，高于市场预期。该行将业绩纳入新预测，并将目标价由500.7港元上调至626.4港元。维持“跑赢大市”评级。报告指，科伦博泰管理层维持2026年全年销售指引，预期商业化收入至少较2025年翻倍。公司引入新的肿瘤治疗模式，而sac-TMT于2027年前全球上市仍是未来的关键催化剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-19/doc-ininvmyq8373324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EWH","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158710620","title":"异动解读｜科伦博泰生物盘中下跌3.04%，利润含一次性收入致获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1158710620","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158710620?lang=zh_cn&edition=full","pubTime":"2026-08-19 11:23","pubTimestamp":1787109835,"startTime":"0","endTime":"0","summary":"8月19日，科伦博泰生物盘中下跌3.04%，报526.0港元，成交额8796.1万港元。公司股价在前一交易日因中期业绩超预期上涨约4%后出现回调。消息面上，虽然公司上半年净利润3.88亿元实现扭亏为盈，但高盛研报指出，该利润主要来自与MediLink的7.02亿元和解收入及美国预扣税退税1.4亿元等一次性项目。科伦博泰生物是一家主要从事肿瘤学、免疫学领域创新药物研发、制造及商业化的公司，核心产品包括TROP2 ADC芦康沙妥珠单抗等。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"科伦博泰生物盘中下跌3.04%，利润含一次性收入致获利回吐","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":-0.0488},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.244},{"period":"6month","weight":0.2672},{"period":"1year","weight":-0.0041},{"period":"ytd","weight":0.2478}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0276},{"period":"6month","weight":-0.0041},{"period":"1year","weight":0.0236},{"period":"ytd","weight":0.0008}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四川科伦博泰生物医药股份有限公司是一家主要从事新药业务的研发、生产和销售的中国公司。该公司主要从事肿瘤学、免疫学及其他治疗领域的创新药物的研发、制造及商业化。该公司的产品有抗体药物偶联物（ADC）SKB264和A166等。该公司产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等疾病的治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.05939},{"month":2,"riseRate":0.666667,"avgChangeRate":0.239909},{"month":3,"riseRate":1,"avgChangeRate":0.292496},{"month":4,"riseRate":1,"avgChangeRate":0.083557},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.011152},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.022649},{"month":7,"riseRate":0.666667,"avgChangeRate":0.111158},{"month":8,"riseRate":1,"avgChangeRate":0.042518},{"month":9,"riseRate":0.75,"avgChangeRate":0.059655},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.03489},{"month":11,"riseRate":1,"avgChangeRate":0.072292},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053467}],"exchange":"SEHK","name":"科伦博泰生物","nameEN":"SKB BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦博泰生物,06990,科伦博泰生物股票,科伦博泰生物股票老虎,科伦博泰生物股票老虎国际,科伦博泰生物行情,科伦博泰生物股票行情,科伦博泰生物股价,科伦博泰生物股市,科伦博泰生物股票价格,科伦博泰生物股票交易,科伦博泰生物股票购买,科伦博泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}